Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Canopy Growth ( (TSE:WEED) ) just unveiled an announcement.
On May 15, 2026, Canopy Growth announced that it expects to release its fourth‑quarter and full‑year results for the period ended March 31, 2026, before markets open on June 15, 2026, and will simultaneously present restated financials for fiscal 2025 and 2024. These restatements stem from a technical, non‑cash accounting error in which certain U.S. dollar‑denominated, share‑settled warrants issued in fiscal 2024 were misclassified as equity rather than liabilities.
The company emphasized that the corrections are limited to reclassifications between equity and liabilities and related fair value adjustments, with no impact expected on revenue, margins, operating income or loss, cash flows, key non‑GAAP metrics, assets, liquidity, or debt covenant compliance. To manage the process, Canopy Growth has applied for a management cease trade order affecting certain directors and officers until the refiling is complete, while pledging bi‑weekly status updates so that investors and other stakeholders remain informed as the accounting issue is resolved.
The most recent analyst rating on (TSE:WEED) stock is a Buy with a C$2.00 price target. To see the full list of analyst forecasts on Canopy Growth stock, see the TSE:WEED Stock Forecast page.
Spark’s Take on WEED Stock
According to Spark, TipRanks’ AI Analyst, WEED is a Neutral.
The score is held back primarily by weak financial performance (shrinking revenue, large losses, and ongoing cash burn). Offsetting this, the earnings call indicates tangible progress via cost reductions, improved liquidity, and a stated path to positive adjusted EBITDA in FY2027, while technicals show positive momentum but are tempered by overbought signals.
To see Spark’s full report on WEED stock, click here.
More about Canopy Growth
Canopy Growth is a world-leading cannabis company focused on both recreational and medical markets, offering a portfolio of owned and licensed brands such as Tweed, 7ACRES, DOJA and Storz & Bickel. The company is Canada’s leading provider of medical cannabis services via Canada House Clinics and Abba Medix and also holds a non‑controlling interest in Canopy USA, providing exposure to the U.S. THC market.
Committed to quality, responsible use and community engagement, Canopy Growth develops and distributes innovative cannabis products across Canada and selected international markets. The company positions itself as a key player in shaping the future of cannabis as a mainstream wellness and lifestyle category.
Average Trading Volume: 2,054,303
Technical Sentiment Signal: Strong Sell
Current Market Cap: C$669.1M
Learn more about WEED stock on TipRanks’ Stock Analysis page.